Advertisement
Advertisement

  

HIV JournalView



  • HIV JournalView (October/November 2004)
    David Wohl, M.D., reviews a quintet of recently published studies on mortality, HIV treatment initiation, the tenofovir-associated K65R mutation, viral loads and sexual risk behavior, and cesarean delivery in HIV/hepatitis C-coinfected patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September 2004)
    Mark Holodniy, M.D., F.A.C.P., C.I.C., examines 7 recently published studies, including new research on sperm washing, enfuvirtide (T-20, Fuzeon) resistance mutations and two experimental lipodystrophy treatments: suction-assisted lipectomy and exogenous growth hormone.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (August 2004)
    David Wohl, M.D., examines the therapeutic effects of acetyl-L-carnitine on distal peripheral neuropathy; the growing prevalence of HIV drug resistance, and the lack of corresponding impact on CD4+ cell count and viral load; the use of niacin as a safe alternative to statins for hyperlipidemia; and risk factors associated with the widely reported HIV outbreak in North Carolina among black, college-age men who have sex with men.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (July 2004)
    Keith Henry, M.D., analyzes 12 published studies on a wide array of topics, including the risks of sexual transmission during acute infection; the prospects of successful treatment after failing a protease inhibitor-based HAART regimen; and a possible explanation for why the enigmatic GBV-C slows HIV progression.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (June 2004)
    David Wohl, M.D., analyzes several recently published studies on the occurrence, impact and transmission of drug-resistant HIV and resistance testing.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (May 2004)
    David Wohl, M.D., analyzes newly published research on the clinical implications of viral load "blips," the improvement of lipoatrophy through antiretroviral switching, the use of HAART to treat cognitive impairment and the ramifications of ACTG 5095.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (April 2004)
    David Wohl, M.D., analyzes newly published research on the impact of GBV-C on HIV progression, long-term data on lopinavir/ritonavir, the use of lipid screening by healthcare providers and updated figures on heterosexual HIV transmission in the United States.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 Research Reports of 2003 (February 2004)
    David Wohl, M.D., reviews the top 10 published research reports of 2003.
    To read PDF, click here.
    From TheBodyPRO.com

  • < Previous | 1 | 2 | 3


  
Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.